*Dr. Pauline Gee, Ph.D. Appointed Vice President and General Manager; Anosheh Amery Appointed Vice President of Sales and Marketing
GOLDEN, Colo., CeMines, Inc. today announced that Pauline Gee, Ph.D., (52), has been appointed Vice President and General Manager of the Company's BioSystems Division. Dr. Gee is responsible for the BioSystems Division operations, P&L and building the recently announced product management organization. In addition, CeMines also announced the appointment of Anosheh Amery, (43), as Vice President of Sales and Marketing for its BioSystems Division, reporting to Dr. Gee. The appointments are effective immediately.
Dr. Gee joins CeMines from MDS Pharma Services, a contract drug discovery company, where she was Vice-President of Predictive Biology, responsible for directing the company's chemogenomics and toxicogenomics efforts. Prior to joining MDS Pharma Services, Dr. Gee was President and CEO of Xenometrix, Inc., a biotech company pioneering gene expression profiling necessary to describe cellular regulatory responses to compounds. She earned her doctorate in free radical chemistry from Simon Fraser University, in British Columbia, Canada. Her post-doctorate studies focused on analytical chemistry and constructed Ames strains, which were patented in the Biochemistry and Molecular Biology Division at the University of California at Berkeley. Dr. Gee also did post-doctoral work in DNA repair of neurons in the Biological Sciences Department at Stanford University. Pauline will report to Roger Attick, CEO of CeMines, Inc.
Anosheh Amery joins CeMines from Invitrogen, where he was responsible for directing the launch of more than 15 new products. He also managed new- business development, where his responsibilities included the evaluation and strategic planning of new business opportunities. In this roll Anosheh guided Invitrogen's entry into the molecular diagnostics market. Prior to Invitrogen, Mr. Amery was at QIAGEN, where he managed key clinical products for the diagnostic, pharmaceutical, academia and HLA sectors. He received a Bachelor of Science degree in Physiological Sciences from UCLA. He then received an MBA from one of the most prestigious graduate business schools in Europe, SDA Bocconni in Milan, Italy.
"CeMines has advanced our CellCorrect(TM) product family pre-market development and clinical studies at a head-spinning pace," said Roger Attick, CEO of CeMines, Inc. "At this stage of a company's growth, it is critical to perform an introspective evaluation of strengths and weaknesses. Our evaluation concluded it was time to add key expertise and management depth." Mr. Attick then added: "We are about to begin a substantial transition from R&D and prototypes, to global commercialization of a novel family of clinical cancer products. The time is now to adopt more disciplined and rigorous product management, commercialization 'best-practices,' theranostics platform R&D, and execute on our partnering strategy as we organize clinical sales channels, international marketing alliances and related distribution agreements."
About CeMines, Inc.
CeMines, Inc. is a Life Sciences Systems Biology company, specializing in cell regulatory network research and molecular diagnostics R&D that is principal to commercialization of novel clinical products for worldwide use in diagnosis, treatment and prevention of cancer. The company was founded in 2000 by Dr. Toomas Neuman, Ph.D., Dr. Kaia Palm, Ph.D., and Mr. Richard Cavalli. Company headquarters are located in Golden, Colorado. CeMines' Diagnostics and Theranostics R&D is located in La Jolla, California, and the company's European Union-based subsidiary of CeMines International, CeMines Estonia OU, is located in Tallinn, Estonia.
Forward-Looking Statements
Any statements in this press release about future expectations, plans or prospects for the company, including the company's expectations and plans to complete the FDA review and clearance process and CE Marking in the EU for CellCorrect LAb, constitute 'Forward-Looking' statements. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in these and previous statements. Forward-looking statements should be evaluated along with other information released by the company.
Comments